arrow
K

Koichi Azuma

Kurume University School of Medicine
H指数:53
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Regimen selection for combined immunotherapy in non-small cell lung cancer with PD-L1 < 1%: a multicenter, retrospective study from Japan (SPIRAL-LT1)

PD-L1<1%的非小细胞肺癌联合免疫治疗方案选择:一项来自日本的多中心回顾性研究(SPIRAL-LT1)

2026-10-160
OAAI
Real-World Outcomes and Early Progressive Disease Analysis of Nivolumab and Ipilimumab Combination Therapy in Metastatic NSCLC: LIGHT-NING Study 2.5-year update

真实世界结局和早期进展性疾病分析:纳武利尤单抗联合伊匹木单抗治疗转移性非小细胞肺癌的LIGHT-NING研究2.5年更新

2026-10-130
OAAI
Impact of metabolic dysfunction-associated steatotic liver disease on the development of hepatocellular carcinoma after HCV cure

代谢功能障碍相关脂肪性肝病对HCV治愈后肝细胞癌发展的影响

2026-10-090
OAAI
Phase II Study of Cisplatin/Gemcitabine Plus Necitumumab for Squamous NSCLC After ICI-Platinum Therapy (WJOG14120L)

WJOG14120L研究:接受ICI-铂类方案治疗后鳞状非小细胞肺癌患者接受顺铂/吉西他滨联合尼昔妥木单抗治疗的II期研究

2026-10-010
OAAI
Long-Term Mortality Following Hepatitis C Cure in a Real-World Multinational Cohort

丙型肝炎治愈后的长期死亡率:一项真实世界跨国队列研究

2026-02-220
PRE
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study

免疫检查点抑制剂诱导的间质性肺病(合并与不合并CTLA-4方案)在PD-L1 < 1 %的非小细胞肺癌患者中的研究:一项多中心、回顾性研究

2025-09-260
PRE
Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial

在ADRIATIC III期试验中,日本局限性小细胞肺癌患者在接受同步化放疗后的Durvalumab治疗

2025-09-210
OAAI
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B Study

一项关于阿法替尼与培美曲塞和卡铂联合治疗EGFR突变阳性、非鳞状、晚期非小细胞肺癌(NSCLC)患者(对一线奥希替尼治疗耐药)的II期研究:NEJ025B研究

2025-08-200
PRE
Five-Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment

慢性乙型肝炎合并肾功能不全患者转换为替诺福韦艾拉酚胺后的五年疗效及肾脏安全性

2025-08-090
OAAI
Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer

中度症状性肺炎后 durvalumab 再给药对局部晚期非小细胞肺癌的影响

2025-06-010
PRE
Long-Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct-Acting Antivirals
2025-02-020
PRE
A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET)

一项索托拉西布联合卡铂和培美曲塞治疗携带KRAS G12C突变、晚期非鳞状NSCLC患者的单臂II期研究(WJOG14821L, SCARLET)

2025-01-170
OAAI
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
2024-11-011
PRE
The potential of VEGF-A in the peripheral blood serum as a biomarker of response in the addition of bevacizumab with chemotherapy-combined immunotherapy for metastatic nonsquamous non-small cell lung cancer

外周血血清中VEGF-A作为生物标志物的潜力,用于评估贝伐珠单抗联合化疗与免疫疗法相结合对转移性非鳞非小细胞肺癌的治疗反应。

2024-09-010
PRE
Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study
2024-06-170
OAAI
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
2024-01-015
OA